Skip to main content
Home > BioCentury on BioBusiness > Finance/Investment

Chronological Index of : Finance

 Current Issue
  • Figure: Money Raised in 2015

    From pore to rich Money Raised in 2015 Last week, the biotech industry raised $1,421 million, bringing to $63.9 billion the total raised year-to-date. In 2014, a total of $54.8 billion was raised, including $21.5 …

    Published on 7/27/2015
  • Table: Earnings on deck

    From pore to rich Earnings on deck At least 29 biotechs and pharmas are expected to report earnings this week. (A) 1H14 EPS; (B) Fiscal 1Q earns; (C) Baxalta Inc. (NYSE:BXLT) spun out from Baxter International Inc…

    Published on 7/27/2015
  • From pore to rich

    How Oxford Nanopore regained the U.K.'s top private money raised spot

    Ebb & Flow Ebb & Flow From pore to rich Figure: Money Raised in 2015 Table: Earnings on deck Oxford Nanopore Technologies Ltd. has chosen investors that look more like a public company's — and now the nanopore…

    Published on 7/27/2015
  • Athyrium doubles down

    Why Athyrium thinks its $1.2B fund is in the structured finance sweet spot

    Ebb & Flow Athyrium doubles down Athyrium Capital Management expects its newly closed $1.2 billion fund has found the sweet spot for infusing structured capital into commercial-stage healthcare companies. Athyrium…

    Published on 7/27/2015
  • Gestalt of the times

    Why Sofinnova Ventures is entering asset-centric investing

    Ebb & Flow Gestalt of the times Sofinnova Ventures is jumping on the asset-centric bandwagon with the creation of Dauntless Pharmaceuticals Inc. While the model has been around for a decade, Sofinnova decided to …

    Published on 7/27/2015
  • Strengthening the (Immuno)core

    How Immunocore attracted the biotech industry's biggest-ever series A

    Finance Strengthening the (Immuno)core The moral of the biggest series A round in the history of biotech is that playing nicely with checkpoint inhibitors and other cancer therapies can create significant value. …

    Published on 7/20/2015
  • Figure: Money Raised in 2015

    Many happy returns Money Raised in 2015 Last week, the biotech industry raised $1,782 million, bringing to $62.4 billion the total raised year-to-date. In 2014, a total of $54.8 billion was raised, including $21.5…

    Published on 7/20/2015
  • Table: Earnings on deck

    Many happy returns Earnings on deck At least 16 biotechs are expected to report earnings this week. (A) Core EPS for 1H14; (B) Fiscal 1Q15 Company Date Pre/post mkt 2Q15 EPS est 2Q14 EPS Expected chg …

    Published on 7/20/2015
  • Many happy returns

    Totting up investor returns on Receptos following Celgene's acquisition offer

    Finance Ebb & Flow Many happy returns Figure: Money Raised in 2015 Table: Earnings on deck A postmortem on Receptos Inc. (NASDAQ:RCPT) shows participants in each and every financing event for the company have …

    Published on 7/20/2015
  • On time Arivale

    Why Arch, Polaris think the time is right to bet on scientific wellness

    Finance On time Arivale Venture backers of Arivale Inc. say creating a "scientific wellness" company was impossible as recently as five years ago, and that a confluence of biology and consumer appetite justified …

    Published on 7/20/2015
  • Risk-seeking behavior

    Why Clarus, Novo created a new risk-sharing biotech

    Finance Risk-seeking behavior Clarus Ventures' third disclosed risk-sharing start-up looks to be its broadest so far, as Nuvelution Pharma Inc. expects to tackle a wider variety of diseases and may absorb more risk…

    Published on 7/20/2015
  • Box: The Score from Greece

    Accelerating investor interest The Score from Greece U.S. West footballers ignore drought, rain shots on goal against austerity beleaguered Southern European squad to claim bragging rights at Biotechnologia 2015. …

    Published on 7/13/2015
  • Figure: Money Raised in 2015

    Accelerating investor interest Money Raised in 2015 Last week, the biotech industry raised $742 million, bringing to $60.4 billion the total raised year-to-date. In 2014, a total of $54.8 billion was raised, …

    Published on 7/13/2015
  • Table: 2H15 milestones

    Big news 2H15 milestones Selected products with clinical or regulatory milestones expected in 2H15. Source: BCIQ: BioCentury Online Intelligence Company Product Indication Event Milestone AbbVie Inc. (NYSE:…

    Published on 7/13/2015
  • Big news

    Biotech names and milestones investors like heading into 2H15

    The second half of 2015 includes a host of milestones that could put biotech bellwethers on a steeper upward trajectory.

    Published on 7/13/2015
  • Mid-cap hot streak

    Biotech winners, losers in 2Q15

    Mid-cap biotechs posted the best performance in 2Q15, again outpacing their large-cap brethren.

    Published on 7/13/2015
  • Tiers, some fears

    Buysiders expect biotech mid-caps to find favor with generalists in 3Q15

    Bankers and buysiders expect generalists to move down to the next biotech market cap tier, as the sector's bull run nears 6 1/2 years.

    Published on 7/13/2015
  • Figure: London vs. Europe

    Mid-cap hot streak London vs. Europe The BioCentury Europe gained 7% in 2Q15, while the BioCentury London was up 4%. While decliners beat advancers 13 to 6 in the BC Europe index, the market cap-weighted benchmark…

    Published on 7/13/2015
  • Figure: Price-to-earnings: BT vs RX

    Mid-cap hot streak Price-to-earnings: BT vs RX The average P/E for big biotechs was 26.2 at the end of 2Q15, up 5% from 24.9 in 1Q and 22% higher than the 10-year historical average of 21.5. Notably, the P/E for …

    Published on 7/13/2015
  • Figure: Results by market cap

    Mid-cap hot streak Results by market cap All market cap tiers above $200 million posted gains in 2Q. The top tier — companies valued above $5 billion — gained 3% and was led by a 22% move by Actelion Ltd. (SIX:…

    Published on 7/13/2015
  • Table: 2Q approvals

    Mid-cap hot streak 2Q approvals Selected second quarter approvals. Company Approval Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) EC approves an expanded label for Soliris eculizumab to treat transfusion-…

    Published on 7/13/2015
  • Table: Index performance

    Mid-cap hot streak Index performance Index 2Q15 1H15 NASDAQ Biotechnology 7% 22% BioCentury Europe 7% 20% BioCentury 100 6% 26% NYSE Arca Biotechnology 5% 22% BioCentury London 4% 6% NASDAQ …

    Published on 7/13/2015
  • Table: Restructuring watch

    Mid-cap hot streak Restructuring watch At least five companies reported workforce reductions in the second quarter compared to at least four in the same period last year. All cash and operating loss figures in $M.…

    Published on 7/13/2015
  • Figure: Biotech fund flows

    Tiers, some fears Biotech fund flows About $1.6 billion flowed into biotech funds last quarter, bringing total net inflows for the first half to $5.7 billion. This compares with $2.8 billion of net inflows in 1H14…

    Published on 7/13/2015
  • Figure: Raging bull

    Tiers, some fears Raging bull The biotech bull market now stands at 6.4 years, longer than any bull run since BioCentury created the BioCentury 100 index in the early 1990s. The next longest run, in 2003-08, …

    Published on 7/13/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993